Literature DB >> 11248613

Preliminary evaluation of calcium hydroxylapatite as a transurethral bulking agent for stress urinary incontinence.

R Mayer1, M Lightfoot, I Jung.   

Abstract

OBJECTIVES: To evaluate the potential of calcium hydroxylapatite particles as a bulking material for the treatment of stress incontinence.
METHODS: Ten women (mean age 68 years, range 60 to 82) with stress incontinence associated with intrinsic sphincter deficiency and limited hypermobility were treated with one (3 patients) or two (7 patients) injections of calcium hydroxylapatite particles and were followed up for 1 year subsequent to the last injection.
RESULTS: The mean total volume injected was 3.9 mL. No significant safety issues were identified with regard to local pain, infection, induration, or obstruction. Seven women reported substantial improvement using many fewer pads or none at all (3 patients) at 1 year, 2 women reported fewer pads, and 1 patient reported no change. The daily mean pad use declined from 2.59 to 1.64 and the mean 24-hour pad weight declined by more than 90% (104.9 versus 1.5 g). The mean Valsalva leak point pressure (VLPP) increased from 39 to 46 cm H(2)O at 12 months, with 2 patients dry on testing.
CONCLUSIONS: The results of this small initial study suggest that calcium hydroxylapatite particles have potential as a bulking agent for the treatment of stress incontinence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248613     DOI: 10.1016/s0090-4295(00)01098-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  12 in total

1.  Endoscopic subureteral injection treatment with calcium hydroxylapatite in primary vesicoureteral reflux.

Authors:  Bilal Eryildirim; Fatih Tarhan; Uğur Kuyumcuoğlu; Erkan Erbay; Gökhan Faydaci
Journal:  Int Urol Nephrol       Date:  2007       Impact factor: 2.370

2.  Current use of injectable agents for female stress urinary incontinence.

Authors:  Sender Herschorn
Journal:  Rev Urol       Date:  2005

3.  Long-term outcome of transurethral injection of hyaluronic acid/dextranomer (NASHA/Dx gel) for the treatment of stress urinary incontinence (SUI).

Authors:  Farah Lone; Abdul H Sultan; Ranee Thakar
Journal:  Int Urogynecol J       Date:  2010-06-23       Impact factor: 2.894

Review 4.  Treatment of stress urinary incontinence: recent developments in the role of urethral injection.

Authors:  Philip van Kerrebroeck; Flip ter Meulen; Elisabeth Farrelly; Gregor Larsson; Lena Edwall; Aino Fianu-Jonasson
Journal:  Urol Res       Date:  2003-01-30

5.  Combination of calcium hydroxyapatite and autologous blood for endoscopic treatment of vesicoureteral reflux in children.

Authors:  Roozbeh Tanhaeivash; Abdol-Mohammad Kajbafzadeh; Atefeh Zeinoddini; Neda Khalili; Mona Vahidi Rad; Reza Heidari
Journal:  Int Urol Nephrol       Date:  2014-02-20       Impact factor: 2.370

6.  Injectable synthetic calcium hydroxylapatite ceramic microspheres (Coaptite) for passive fecal incontinence.

Authors:  E Ganio; F Marino; I Giani; A Realis Luc; G Clerico; E Novelli; M Trompetto
Journal:  Tech Coloproctol       Date:  2008-06-10       Impact factor: 3.781

7.  Long-term results of endoscopic treatment of vesicoureteral reflux with the sub-ureteric injection of calcium hydroxyapatite.

Authors:  Tufan Tarcan; Ilker Tinay; Yusuf Temiz; Ferruh Simşek
Journal:  Int Urol Nephrol       Date:  2007-06-30       Impact factor: 2.370

Review 8.  Emerging periurethral bulking agents for female stress urinary incontinence: is new necessarily better?

Authors:  Jonathan S Starkman; Harriette Scarpero; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2006-09       Impact factor: 2.862

Review 9.  Injectable agents: present and future.

Authors:  Deborah J Lightner; Nancy B Itano; Susan D Sweat; Kristin L Chrouser; Felecia Fick
Journal:  Curr Urol Rep       Date:  2002-10       Impact factor: 2.862

Review 10.  Use of calcium hydroxylapatite (Radiesse) for facial augmentation.

Authors:  Patricio F Jacovella
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.